Information Provided By: 
Fly News Breaks for June 22, 2017
ESPR
Jun 22, 2017 | 08:24 EDT
Citi analyst Joel Beatty noted the 19% advance in Esperion shares yesterday, which he said may be related to favorable comments management made at an investor conference regarding the fixed dose combination of Bempedoic Acid with Zetia. Beatty, who continues believe phase 3 results in mid-2018 are likely to be successful, noted that management plans to share more on the combo pill next week. He keeps a Buy rating on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
